title: Preparation and characterization of solid dispersions of carvedilol with PVP K30.
abstract: Solid dispersions in water-soluble carriers have attracted considerable interest as a means of improving the dissolution rate, and hence possibly bioavailability, of a range of hydrophobic drugs. The poor solubility of carvedilol leads to poor dissolution and hence variation in bioavailability. The purpose of the present investigation was to increase the solubility and dissolution rate of carvedilol for enhancement of oral bioavailability. In the present investigation solid dispersions with PVP K30 were prepared by solvent evaporation method. The physical mixture and solid dispersion (s) were characterized for drug-carrier interaction, drug content, solubility and dissolution rate. The solubility of drug increased with increasing polymer concentration. The dissolution rate was substantially improved for carvedilol from its solid dispersion compared with pure drug and physical mixture. As indicated from X-ray diffraction pattern and DSC thermograms carvedilol was in the amorphous form, which confirmed the better dissolution rate of solid dispersions. The solid dispersion was stable under accelerated storage conditions. The solid dispersion technique with PVP K30 as a carrier provides a promising way to enhance the solubility and dissolution rate of carvedilol.
authors: Bhupal Nobles, College of Pharmacy, Udaipur - 313 001, Rajasthan, India.
authors: A
authors: A
authors: Sharma
authors: C P
authors: CP
authors: Jain
references: AAPS PharmSciTech. 2008;9(2):425-30
references: 18431667
references: Cardiovasc Drugs Ther. 1997 May;11 Suppl 1:247-56
references: 9211017
references: Pharm Dev Technol. 2007;12(1):43-53
references: 17484143
references: Acta Pharm. 2007 Jun;57(2):151-9
references: 17507312
references: Acta Pharm. 2009 Jun;59(2):121-32
references: 19564138
references: Pharm Res. 2004 Oct;21(10):1762-9
references: 15553220
references: Drugs. 1997 Jul;54(1):161-85
references: 9211087
references: Drug Dev Ind Pharm. 2007 Aug;33(8):888-99
references: 17729107
references: AAPS PharmSciTech. 2006 Jun 16;7(2):E55
references: 16796372
references: Pharm Acta Helv. 1986;61(3):69-88
references: 3520598
references: J Pharm Sci. 1971 Sep;60(9):1281-302
references: 4935981
references: Drug Dev Ind Pharm. 2005 Sep;31(8):785-94
references: 16221613
references: Int J Pharm. 2002 Mar 20;235(1-2):17-33
references: 11879736
references: J Pharm Pharmacol. 1975 Jan;27(1):48-9
references: 235616
references: Eur J Pharm Sci. 2002 May;15(4):347-53
references: 11988396
references: Mol Pharm. 2004 Jan 12;1(1):85-96
references: 15832504